Australian (ASX) Stock Market Forum

PME - Pro Medicus

Jump to new
galumay said:
No doubt a contract worth just $2.5m per year in revenue will cause the market cap to jump by at least $100m?!
Click to expand...
crazy valuations and moves here , typical of a 'growth ' stock ( including paying very low or no returns at the current share price )
 
21st November 2023
• Co-founders Dr Sam Hupert and Mr Anthony Hall have each sold 1 million PME shares during the current trading window
• The sale represents less than 4% of their respective shareholdings.
• The transaction, in response to an approach from an individual fund, was conducted at the closing market price on the 20th November 2023 of $88.02
• Dr Hupert and Mr Hall remain the two largest shareholders in the company with both founders retaining in excess of 25 million shares each.
• Their combined shareholdings after the sale represent 48% of the company’s shares on issue.
The Pro Medicus Board has been advised that co-founders Dr Sam Hupert and Mr Anthony Hall have sold 1 million shares each in the current trading window representing less than 4% of their individual holdings.
The sale was in response to a strong approach from an individual fund and was done before market at the previous day’s closing price (0% discount). Dr Hupert and Mr Hall are actively engaged in the company as executives and board members and are committed to its future. They remain the two key stake holders in the company with their combined holding post this recent sale of 48%
Dr Hupert and Mr Hall re-affirmed that they do not intend to sell any further shares in PME in the foreseeable future.
The Chairman of the Board, Mr Peter Kempen AM, noted that this sale of shares by the Founders is consistent with previous sales.
This provides prospective shareholders with the opportunity to invest in the Company and ultimately will lead to an increase in the “free float””.

Approved by the Chairman of the Board

i hold PME ( 'free-carried' )

given the increasing tendency of funds ( and ETF providers ) to lend out shares to short-term traders , i hope they know what they are doing

since the share price is currently above $80

surely a share-split say 1 into 5 or 1 into 10 would be a better way ' to increase the free float 'without losing majority control of the company
 
“AI, the words on everybody's lips. It has been around in radiology for quite a while. Medicine and AI are well suited to each other, and imaging and AI, even better suited. Of the FDA [U.S. Food & Drug Administration] cleared algorithms, roughly 80% that have been cleared in health care are in health care imaging. So, it is the hot area at the moment”
- Sam Hupert, CEO, Pro Medicus Ltd

​
 
rise and rise

Screenshot_20240123-111404_CommSec.jpg
 
just defies sensible investment metrics

not as bad as some since it actually makes a profit and pays dividends ( which look hilariously tiny @ $100 plus a share )

is this only the instos soaking the profit-taker's shares ( those who bought at $50 and below )
 
Visage Launches Visage Ease VP™ for Apple Vision Pro

5th February 2024

HIGHLIGHTS
 Visage has launched the groundbreaking Visage Ease VP for Apple Vision Pro
 Visage Ease VP supports immersive, spatial experiences for diagnostic imaging and multimedia
 Visage’s cinematic rendering engine is natively available in Visage Ease VP providing stunning volume-rendered images in immersive space
 Visage Ease VP provides an end-user imaging experience that’s unlike any other application Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its whollyowned U.S. subsidiary, Visage Imaging, Inc., has announced the launch of the groundbreaking Visage Ease VP for Apple Vision Pro, Apple’s highly anticipated spatial computing platform.
Designed to take advantage of the unique capabilities of Apple Vision Pro, Visage Ease VP supports immersive, spatial experiences for diagnostic imaging and multimedia.
Visage Ease VP includes all the proven functionality of Visage Ease™, plus the exciting addition of Visage’s powerful cinematic rendering engine for stunning volume-rendered images in immersive space.
Anywhere, on-the-go access with Visage Ease VP has additional flexibility with virtual screens at more than 4K resolution for each eye, independence from environmental lighting restrictions, and the ability to interact with imaging seamlessly in your physical space.
Visage Ease VP uses the natural and intuitive input of eyes, hands, and voice navigation to provide an end-user imaging experience that’s unlike any other application.

UC San Diego Health, a Tier 1 academic medical center and Visage customer, is the first health system to pilot the technology.
“The visualization of three-dimensional medical imaging in immersive space creates exciting opportunities to improve patient care,” said Dr. Paul Murphy, associate clinical professor at UC San Diego School of Medicine and radiologist at UC San Diego Health.
“Technology that allows for sophisticated eye motion and gesture controls for reviewing 2D and 3D medical imaging could potentially help in efficient tumor board reviews and create collaborative spaces in healthcare.
” Today’s launch of Visage Ease VP ushers in a new era of spatial imaging and workflow possibilities.
“Visage’s platform of enterprise imaging applications that support the Apple ecosystem are used by many of the world’s largest, most sophisticated healthcare organizations, and also integrated bidirectionally to the most widely used EHR,” said Malte Westerhoff, PhD,

Visage co-founder and global chief technology officer. “With Visage Ease VP we can now extend our offering to immersive, spatial imaging which has the potential to open up a number of novel and exciting possibilities within both medical imaging and the wider healthcare space.”
Visage Ease VP (visionOS) is the latest member of the Visage Ease family of native apps purposebuilt for the Apple ecosystem, joining Visage Ease (iOS/iPadOS) and Visage Ease Pro™ (iPadOS). Visage also offers the acclaimed Visage 7 smart-client application for macOS, providing native, ultrafast, clinically rich, highly interoperable access to enterprise imaging.
Visage Ease VP is exclusively intended for use by Visage customers on the industry-leading Visage® 7 Enterprise Imaging Platform, version Visage 7.1.18h (or higher).

For more information, please visit the Visage website: https://visageimaging.com/platform/visageon-apple.

Authorised by the Board of Pro Medicus Limited.

i hold PME ( 'free-carried' )

and it has touched a new high of $108.500 on a down day

still ridiculously over-priced in my opinion but buying them they are
 
Pro Medicus Limited interim results
Thursday 15 February 2024

HIGHLIGHTS
 Revenue from ordinary activities $74.1m – up 30.3%
 Underlying profit before tax $48.9m – up 31.5%
 Net profit $36.3m – up 33.3%
 Cash and other financial assets $131.5m – up 8.3%
 Company remains debt-free
 Fully-franked interim dividend 18c per share

Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a half-year net profit of $36.3 million for the six months to the end of December 2023, 33.3% higher than for the previous corresponding period.
Revenue from ordinary activities was $74.1 million, up 30.3%.
The company’s cash and other financial assets at December 2023 were $131.5 million, an increase of 8.3%.
Pro Medicus announced a fully-franked interim dividend of 18c per share.
The company remains debt-free.
The result was largely driven by increased revenue from North America (revenue up 36.8%), with four major implementations completed.
During the six-month period Pro Medicus also won four key contracts; Memorial Sloan Kettering, Baylor Scott & White, South Shore Health and Oregon Health & Science University.
These contracts have a total contract value of A$200 million (at committed minimum exam volumes) with contract terms ranging from 7 to 10 years.
Pro Medicus CEO Dr Sam Hupert said he was very pleased with the result, which was a record one for the company in terms of revenue and net profit as well as new sales.
“We benefited from above industry growth in exam volumes across our client base and successfully completed four new implementations all of which will provide a full six months of revenue in the second half.
On top of this, we had our strongest start to the year in terms of sales, so, we believe our second half will be stronger than our first forming the base for future growth in FY2025 and beyond.
” Looking ahead, Pro Medicus aims to further build on its presence in North America, Germany and Australia and is actively pursuing a growing number of opportunities across key markets – academic medical centers (AMC), integrated delivery networks (IDN) and corporate/private imaging centres.
“Our pipeline is strong across all sectors of the market,” Dr Hupert said. “Our cloud-based modular approach continues to provide unprecedented flexibility and scalability, as evidenced by the increasing number of clients choosing the full stack of all three Visage products – Viewer, Workflow and Archive, a trend we see continuing.”

Authorised by the Board of Pro Medicus Limited.

i hold PME ( 'free-carried' )

IMO ridiculously over-priced

but 🤣 the six moth div. is now more than what i paid for the shares , 200% ( plus ) ROI per year , how crazy is that
 
PME signs five new contracts with a combined minimum value of A$45.0M

HIGHLIGHTS
 Signs five new customer contracts with a combined minimum value of A$45.0M
 Broad range of customers - multiple segments of the market
 New contracts are transaction-based with potential upside Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly owned U.S. subsidiary, Visage Imaging, Inc., has signed five new contracts with a combined minimum contract value of A$45.0M.
The contracts will be fully Cloud deployed and are expected to be completed within the next 6 months:
 A $9.5M, 5-year contract with Consulting Radiology, a private radiology group in Minnesota
 A $11.5M, 7-year contract with Nationwide Children’s Hospital, a leading paediatric hospital in Columbus, Ohio
 A $6.5M, 5-year contract with Nicklaus Childrens Hospital, a leading paediatric hospital in Miami, Florida
 A $9M, 8-year contract with Moffitt Cancer Center, in Tampa, Florida
 A $8.5M, 5-year contract with US Radiology Specialists, a partnership of physician owned radiology practices.

The contracts bring the company’s minimum total contract value (TCV) for new sales this financial year to $245 million.

Referring to the new clients, Dr Hupert commented, “They are a diverse group, two children’s hospitals, two physician led private radiology groups and a cancer center.

This reinforces our belief that our product is ideally suited to virtually all segments of the market from smaller groups all the way though to some of the largest IDN’s and academic medical centers in the US”.
Dr Hupert concluded, “Despite record new contract signings this year, our pipeline remains strong with a broad range of opportunities both in terms of size and market segments”.

Authorised by the Board of Pro Medicus Limited.

i hold PME ( 'free-carried' )
 
Pro Medicus Limited full year results

14 August 2024

HIGHLIGHTS
 Revenue from ordinary activities $161.5m – up 29.3%
 Underlying profit before tax $116.5m – up 35.3%
 Net profit $82.8m – up 36.5%
 Underlying EBIT margins increase to 69.5% (FY23: 67.2%) Cash and other financial assets $155.4m – up 27.9%
 Company remains debt-free
 Fully franked final dividend 22c per share

Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a full-year net profit of $82.8 million for the year to the end of June 2024, 36.5% higher than for the previous corresponding period.
Revenue from ordinary activities was $161.5 million, up 29.3%.
The company’s cash and other financial assets at the end of June 2024 were $155.4 million, up $33.9 million, an increase of 27.9%.
Pro Medicus announced a fully franked final dividend of 22c per share, making the full year dividend 40c fully franked, an increase of 33.3%.
The company remains debt-free.
The result was driven by increased revenue from North America up 34.4% and Australia up 5.9%, whilst Europe decreased by 6.7% due to one-off revenue from a sale to a German hospital in the previous corresponding period.
During the year Pro Medicus made the following key announcements:
 A $24M, 7-year contract with Memorial Sloan Kettering Cancer Centre, a not-for-profit cancer centre that operates 24 inpatient and outpatient locations across the New York City metropolitan region.
 A $140M, 10-year contract with Baylor, Scott and White, the largest not-for-profit health care system in Texas, and one of the largest in the United States.
 A $16M, 8-year contract with South Shore Health, the largest independent health system in Southeastern Massachusetts.
 A $20M, 8-year contract with Oregon Health & Science University, the preeminent academic medical center in Oregon.
 A $9.5M, 5-year contract with Consulting Radiology Limited, a large privately-owned radiology group based in Minneapolis.
 A $11.5M, 7-year contract with Nationwide Children’s Hospital, a leading paediatric hospital in Columbus, Ohio.
 A $6.5M, 5-year contract with Nicklaus Children’s Hospital, a leading paediatric hospital in Miami,Florida.
 A $9M, 8-year contract with Moffitt Cancer Centre a not-for-profit cancer treatment and research centre located in Tampa, Florida.
 A $8.5M, 5-year contract with US Radiology Specialists, a partnership of physician-owned radiology practices and diagnostic imaging centres in Raleigh, North Carolina.
Pro Medicus CEO Dr Sam Hupert said he was very pleased with the result, which represented another record for the company, not only in terms of revenue and net profit, but also sales and implementations.
‘All our key metrics moved in the right direction during the year,’ he said. ‘We won nine contracts, with a minimum total contract value of $245m, ranging from boutique opportunities such as the Florida-based Nicklaus Children’s Hospital through to our biggest sale to date in Baylor, Scott and White the largest not for profit in the state of Texas.
As we have demonstrated, our solution can work across all segments of the market, from a two-person radiology practice in Melbourne all the way to the largest, most sophisticated healthcare enterprises in the US such as Mayo Clinic.
We have a bit over 7% of the total addressable market (TAM) in the US and growing, so there is still a huge amount of runway ahead of us”.
Dr Hupert said the increasing adoption of Cloud has made PME’s implementations more streamlined.
‘In recent years all our implementations have been Cloud-based.
We see this as a strategic advantage for us,as our competition has not been able to re-engineer their systems to be Cloud-native like the Visage suite of products.
The fact that the vast majority of our recent sales have been for our “full stack” – Viewer,Archive and Workflow Management – also impacted positively on the result and augurs well for the future.
’Dr Hupert said he was also pleased with the company’s EBIT margins which have increased from 67.2% last year to 69.5% this year.
‘Our margins are industry leading and have been for many years.
This is a testament to the scalability and high operating leverage of our offering,’ he said.
Pro Medicus continued to make steady progress with its AI and other -ologies, particularly in terms of the company’s research collaborations, and the company’s pipeline remains strong.
‘We have seen an increased cadence of inbound RFPs across a broad range of market segments,’ Dr Hupert said.
‘This, plus an increased focus on Cloud, has helped boost our pipeline, not just in terms of quantity of opportunities but also quality.’

Authorised by the Board of Pro Medicus Limited.

i hold PME ( 'free-carried' )

a nice result , but $135 nice ( has been above $146 this year ) ??
 
and just to get eye-rolls

PME hit a new record high at the close of the day
 

Attachments

  • download (1).gif
    download (1).gif
    181.2 KB · Views: 3
touched a new record high of $160.830 this morning , ex-div. as well so you can't claim the 22 cent div. drove up the price

however my main interest now is if it can break $165 ( my buy price was 16.5 cents ) and make it a THOUSAND BAGGER in just over 13 years

i can just dream of it now .. a custom back patch for my denim jacket ... or maybe a custom belt buckle

maybe i should start a blog ( like Dr. FFF ) and break another email server

oh the fame .. the fortune .. the extra tax forms ...🤢🤢 🤦‍♂️🤦‍♂️🤷‍♂️

maybe i should just go back to researching and looking for the next 100 bagger 🤔🤔
 
$166.960 touched today

one thousand bagger status ( for me ) officially achieved

and i might suggest the market is totally , absolutely nuts

or are we climbing the Wall of Worry ?
 
Pro Medicus announced that the Company's wholly owned U.S. subsidiary, Visage Imaging, has signed an 8-year contract renewal with St Louis based Mercy Health.
The contract has a minimum value of A$98m.
The deal which covers both Visage 7 Viewer and Visage 7 Open Archive is transaction-based and has been negotiated at a higher per transaction cost.

i hold PME ( 'free-carried' )

ho-hum

another month , another contract ( a renewal in this case ) or so it seems

IMHO ridiculously over-priced

but am currently up more than $180 a share , maybe i shouldn't complain so much
 
PME signs $32M, 5-year contract extension with a large Australian Radiology Network
16th October 2024

HIGHLIGHTS
 5-year contract extension with a minimum value of A$32M
 Contract extension is for company’s Visage RIS product
 Contract extension negotiated at an increased fee
Leading health imaging company Pro Medicus Limited [ASX: PME] today announced it has signed a 5-year contract extension with a large Australian Radiology Network.
The contract extension has a minimum value of A$32M and is for the company’s RIS product.
This contract extension cements our leadership position when it comes to RIS in the Australian market” said Dr Sam Hupert, Pro Medicus CEO. “

Authorised by the Board of Pro Medicus Limited.

For further information:Dr Sam Hupert
Chief Executive Officer
Pro Medicus Limited

Phone: +61 3 9429 8800

i hold PME ( 'free-carried' )

ho-hum

another month , another contract ( a renewal in this case ) or so it seems, !*@! my bad , TWO renewals

went as high as $191.750 this morning

i guess $200 is now possible despite the absurdly stretched valuations
 
PME is my December 2024 comp. pick

just put out a great AGM presentation and went Up $5.890 (2.66%) in response to that

now i don't expect members to be buying this at nose-bleed valuations , BUT something that punters might have missed in the presser was they have very limited penetration in the EU and therefore a reasonable path to extra growth in coming years , and folks are paying crazy premiums for growth , in this crazy market/economy maybe it can sign some more contracts in December

i hold PME ( 'free-carried' )

i am currently up more than 137,000% on this ( , and despite selling 95% of the original buy on the way .. it is currently my largest holding , easily ...) who knew i didn't !
 
Top